Stuart N. Atkinson, MB, ChB
Tolmar Pharmaceuticals, Inc.Buffalo Grove, IL
Authored Items
November 2021 Vol 12, No 11
Prostate cancer (PCa) patients treated with injectable androgen deprivation therapy (ADT) are particularly vulnerable during a pandemic because they may not be able to self-administer treatment and may be required to visit a clinic/hospital for injections.
Tina DeNofrio, RN, BSN, OCN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Julia Vandross, NP-BC, BSN, MSN
November 2020 Vol 11, No 11
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used androgen deprivation therapy (ADT) for prostate cancer (PCa).
Julia Vandross, NP-BC, BSN, MSN, Stuart N. Atkinson, MB, ChB, Deborah M. Boldt-Houle, PhD, Tina DeNofrio, RN, BSN, OCN
November 2019 Vol 10, No 11
Luteinizing hormone-releasing hormone (LHRH) agonists are the most frequently used drugs for the delivery of androgen deprivation therapy (ADT) in prostate cancer (PCa).
Julie Prettyman, RN, BSN, CCRC, John A. McLane, PhD, Stuart N. Atkinson, MB, ChB, Allison Tyler, RN, BSN, OCN, CCRP, Deborah M. Boldt-Houle, PhD
November 2018 Vol 9, NO 11
In prostate cancer therapy, achieving and maintaining effective testosterone (T) suppression to the level attained with surgical castration is the cornerstone of androgen deprivation therapy (ADT).
Last modified: December 17, 2021